Prurigo nodularis
☆ AI Dermatology — Free Service
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
relevance score : -100.0%
ReferencesPrurigo nodularis se yon kondisyon po ki dire lontan, ki karakterize pa plizyè boul fèm ak nodil, anjeneral sou bra yo ak janm yo. Boul sa yo ka varye nan koulè, soti nan ton po a rive woz, epi yo koze gratèl entans. Yo ka afekte moun nenpòt laj epi souvan lye ak lòt kondisyon po ki lakòz gratèl kwonik, tankou dermatoz atopik. Opsyon tretman yo gen ladan medikaman anti‑grate fò, dwòg ki afekte sistèm iminitè a, ak medikaman ki vize sistèm nève a. Jere prurigo nodularis anjeneral enplike terapi alontèm.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Tretman anjeneral enplike itilizasyon krèm oswa piki estewoyid sou zòn ki afekte a. Nan ka ki pi grav oswa ki pa reponn a terapi, yo ka rekòmande terapi limyè oswa medikaman ki siprime sistèm iminitè a. Talidomid ak lenalidomid se opsyon pou ka grav, men yo ka lakòz efè segondè grav. Tretman ki pi resan, tankou antagonis reseptè opioid (opioid receptor antagonists) ak antagonis reseptè neurokinin‑1 (neurokinin-1 receptor antagonists), montre pwomès pou trete prurigo nodularis ak pi piti efè segondè konpare ak talidomid oswa lenalidomid.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo se yon kondisyon po ki karakterize pa gratèl ki dire plis pase 6 semèn, blesi po ki gen rapò ak grafouyen, epi ki souvan akonpaye ak yon istwa gratèl souvan. Li enplike neronflamasyon ak fibwoz nan po a.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis se yon pwoblèm po ki dire lontan, ki make pa nodul ki grate. Nou pa konnen egzakteman sa ki lakòz li, men li sanble ke pwoblèm iminitè ak nè yo jwe yon wòl nan sik kote po a ap grate. Kounye a, pa gen okenn tretman ki apwouve pa US FDA espesyalman pou Prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Tretman – Medikaman OTC
Lave zòn blesi a ak savon pa ede ditou epi li ka vin pi mal. Estewoyid OTC ka ede soulaje sentòm yo, men anjeneral li bezwen aplike pandan plizyè semèn pou wè amelyorasyon. Kontinye pran antihistamin tou ede soulaje demanjezon an.
#OTC steroid ointment
#OTC antihistamine
○ Tretman
#Intralesional triamcinolone injection